1. Introduction {#sec1}
===============

Red blood cell distribution width (RDW) is a parameter of anisocytosis or heterogeneity in the volume of circulating erythrocytes and is traditionally used in laboratory hematology for differential diagnosis of anemias, which is easily available from a standard complete blood cell count (CBC) \[[@B1], [@B2]\]. Some recent studies have shown that higher RDW level can predict morbidity and mortality of cardiovascular disease, for example, myocardial infarction, heart failure, and atrial fibrillation \[[@B3]--[@B6]\]. Atrial fibrillation (AF) is one of the most common arrhythmias worldwide, seriously threatens people\'s quality of life, and increases the risk of stroke, heart failure, and death. The incidence and prevalence of AF is significantly increased in China \[[@B7], [@B8]\]. The specific mechanism between the elevated RDW and AF is unclear. Recent studies indicate that inflammatory reaction and oxidative stress play an important role in the connection of RDW and AF \[[@B9]--[@B11]\].

High-altitude exposure is known for its strong ultraviolet light and low oxygen pressure. Among them, hypoxia is closely related to the occurrence and development of cardiovascular diseases, mainly manifested by changes in the structure and function of the cardiovascular system, thereby aggravating the occurrence of cardiovascular diseases \[[@B12]--[@B14]\]. Some studies shown that the mechanisms of cardiovascular disease associated with altitude include mainly sympathetic activation, inflammatory reaction, and oxidative stress \[[@B15]--[@B17]\].

However, there were no data on the association of RDW with different types of nonvalvular AF at different altitude areas. We aimed to investigate the role of RDW as a novel marker for different types of AF at different altitude in China.

2. Methods {#sec2}
==========

2.1. Study Population {#sec2.1}
---------------------

Our study included 303 patients with nonvalvular AF in total, 156 in low altitude (77 paroxysmal AF, PAF; 79 persistent AF, PeAF), 147 in high altitude (77 PAF; 70 PeAF), respectively, and 167 patients without AF (72 in low altitude, 95 in high altitude) matched for sex, age, atherosclerotic risk factors, and history of medicine who were admitted in cardiology department from March 2016 to March 2018 in Second Hospital of Tianjin Medical University and Qinghai Provincial People\'s Hospital from two cities (Tianjin and Xining), respectively. Tianjin is located at 3.5 m. Xining is located at 2260 m above the sea level. AF was defined as absence of *P* waves and irregular R-R interval in a 12-lead electrocardiogram (ECG) or 24 h Holter recording. The different types of AF were defined according to the ESC guidelines for the management of atrial fibrillation \[[@B18]\]. Each subject had at least one ECG showing AF. Exclusion criteria were congenital heart disease, coronary artery disease, cardiomyopathy, concomitant valvular heart disease, previous cardiac surgery, renal insufficiency, thyroid dysfunction, acute or chronic inflammatory disease, hematological diseases, or unavailable medical records. Moreover, patients who had a recent 3-month history of blood transfusion were also excluded.

2.2. Study Protocol {#sec2.2}
-------------------

All baseline demographic, clinical characteristics and laboratory examinations including CBC and transthoracic echocardiography were carefully recorded. CBC testing utilized clinical laboratory methods (Coulter BC-5380/6800 Hematology Analyzer, Mindray, Shenzhen, China) for white blood cell (WBC) count, red blood cell (RBC), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), platelet count (Plt), mean platelet volume (MPV), hemoglobin (Hb) levels, and RDW. Serum creatinine (Cr), uric acid (UA), and total bilirubin levels (TBIL) were measured by using an automatic blood biochemical analyzer (TBA-120 FR analyzer Toshiba, Japan). Both laboratory and biochemical tests were obtained after the second sky-abdomen examination after admission. Left atrial diameter (LAD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were evaluated by a transthoracic echocardiographic examination (the Vivid-7 system USA).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Categorical variables were reported as counts (percentage) and continuous variables as means ± standard deviation. Comparison between groups were used the Student\'s *t*-test or ANOVA with Tukey\'s post hoc test for continuous variables (as appropriate) while categorical variables were tested by Chi square. Multivariate logistic regression analysis was performed to identify the independent predictors of AF. The regression coefficients of the confounders included in the multivariable analysis were used to generate a nomogram for calculating the patient-specific probabilities of the occurrence of AF. Only *P* values \< 0.05 were regarded as statistically significant. The statistical studies were carried out using Statistical Package for Social Sciences software (SPSS 24.0 for Windows, SPSS Inc., Chicago, IL, USA) and R 3.4.3 (The R Foundation, Vienna, Austria).

3. Results {#sec3}
==========

The mean age of the included patients was 68 ± 10 years old, and 49.1% were male. There was no significant difference in age, gender, the presence of diabetes mellitus, hypertension, stroke, and smoking between the groups. Both low and high altitude, the levels of RDW and LAD in patients with AF group were higher than those in the control group (*P* \< 0.05) in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}, and the PeAF group was higher than PAF-group (*P* \< 0.05) in [Table 3](#tab3){ref-type="table"}. RDW, RBC, HCT, MPV, LAD, and LVEF levels were higher in the PAF group, PeAF group, or control group of high-altitude than those of corresponding groups in low altitude ([Table 3](#tab3){ref-type="table"}).

Multivariate logistic regression analysis demonstrated that RDW, MCV, and LAD levels independently associated with AF patients in low altitude (RDW, OR 1.687, 95% CI 1.021--2.789; *P* \< 0.05) in [Table 4](#tab4){ref-type="table"}, while in high altitude, RDW, MCV, Cr, and LAD were independent predictors for AF patients (RDW, OR 1.755, 95% CI 1.179--2.613; *P* \< 0.05) ([Table 5](#tab5){ref-type="table"}).

Therefore, we integrated RDW, MCV, Cr, and LAD into two nomograms for prediction of probability of occurrence of AF in low altitude ([Figure 1](#fig1){ref-type="fig"}) and high altitude ([Figure 2](#fig2){ref-type="fig"}), respectively. For the nomogram, each predictor was assigned a point in the graphic interface of the nomogram, and the total points were assigned as a linear combination of the points of each predictor on a scale from 0 to 100% to find out the corresponding risk of AF.

4. Discussion {#sec4}
=============

The main findings of our study are that AF patients have higher RDW and LAD levels than patients without AF at both high and low altitudes. Moreover, RDW and LAD levels were in high altitude compared to low altitude. Multivariate logistic regression analysis showed that RDW was a risk factor for AF.

RDW represents the variability in the size of circulating red blood cells obtained by an automatic blood count instrument, which measures 100,000 red blood cell volume over ten seconds. A number of studies have reported that RDW is a novel marker for proinflammatory reaction and oxidative stress in the body. The latter may inhibit the maturation of red blood cells, leading to the entry of immature red blood cells into the general circulation, resulting in an increase in the heterogeneity of peripheral red cell morphology \[[@B1], [@B9], [@B19]\]. RDW has been associated with, and used as a prognostic marker for outcomes, in many cardiovascular diseases \[[@B3]--[@B5], [@B20]\]. Liu et al. showed that not only the RDW level in patients with paroxysmal AF was significantly higher than that in the control group, but also related to the CHADS2 and CHA2DS2-VASc scores and thromboembolic risk in patients with AF \[[@B6], [@B21], [@B22]\]. Aksu et al. found that high RDW levels can be used to predict AF recurrence after cryoballoon ablation \[[@B23]\]. Moreover, previous comprehensive systematic reviews and meta-analyses confirmed that increased RDW can predict new-onset and recurrent AF generally, and after isolated coronary artery bypass grafting, valvular surgery, or combined procedures \[[@B24], [@B25]\]. This study found in two altitudes that not only RDW in patients with AF were higher than non AF patients, but also patients with persistent AF had higher levels than patients with paroxysmal AF, speculating that RDW levels were associated with AF subtypes.

The high-altitude environment results in chronic hypoxia. Several studies have shown that hypoxia causes transcription translational changes of multiple genes mediated by transcription mediators such as hypoxia-inducible factors, which in turn leads to imbalance of energy metabolism, neuroendocrine alterations, body fluid imbalance, increased oxidative stress, vascular dysfunction, and consequent pathophysiological changes \[[@B17], [@B26]\]. Indeed, exposure to acute and chronic hypoxic conditions in high altitude, increased sympathetic activation, plasma adrenaline levels, cardiac output, heart rate, and elevated blood pressure ultimately lead to cardiac structure and function change \[[@B27], [@B28]\]. In healthy people, high sympathetic activity that arises from sporting activity can induce atrial or ventricular arrhythmias through mechanisms such as increased automaticity, triggered activity, or reentry \[[@B29]--[@B31]\]. The commonest hematological adaptations are increased adaptive red blood cells and hemoglobin levels and polycythemia, leading to hyperviscosity, impairing the oxygen supply to multiple organs. Hypoxia can stimulate erythropoietin (EPO) synthesis and release that is the main mechanism of the occurrence of high-altitude polycythemia \[[@B26]\]. RDW can weaken the response of bone marrow to EPO and hinder the maturation of red blood cells, eventually leading to an increase in red blood cell volume dispersion. In our study, this may be the explanation as to why the RDW levels of each group in the high-altitude area were higher than the low altitude. The possible mechanism by which hypoxia leads to oxidative stress is increasing the generation of reactive oxygen species (ROS). Due to the limited oxygen supply, less oxygen receives electrons from oxidative phosphorylation, which may lead to accumulate reduction equivalents, and this reducing environment is beneficial to the mass production of superoxide, peroxide, and hydroxyl radicals. However, the potential source of ROS is due to the large-scale activation of xanthine oxidase and phospholipase A~2~, which not only increases the release of NO, but also increases the availability of free iron and increases the release of oxygen free radicals from red blood cells. The balance between the oxidation and antioxidant systems is broken and oxidative stress occurs when too much ROS is produced or antioxidant is depleted \[[@B17], [@B32]--[@B35]\]. Al-Hashem et al. \[[@B16]\] found that compared to low-altitude natural rats, serum inflammatory cytokine levels and urinary norepinephrine levels were significantly increased in high-altitude rats, and while using beta and alpha adrenergic receptor blockers, inflammatory mediator levels is lower. Hartmann et al. \[[@B36]\] found that at 3458 m and 4559 m, interleukin (IL) -6, IL-1, and C-reactive protein (CRP) levels were higher than baseline in healthy people in the short-term. In this study, although the WBC level in high-altitude areas is lower than that in low altitude, the level of RDW is significantly increased which is considered to be related to the sensitivity of WBC to the inflammatory state of the body is not as sensitive as high-sensitive C-reactive protein (hs-CRP) and ILs \[[@B37]\]. Inflammatory reaction and oxidative stress play an important role in the process of high-altitude hypoxia injury.

5. Limitations {#sec5}
==============

Several limitations of our study should be noted. Firstly, this took a cross-sectional design without follow-up, so the impact of RDW on the progression of AF and the occurrence of AF complications has not been explored. Second, a number of inflammatory markers, such as hs-CRP, IL, and tumor necrosis factor, were not evaluated. Thirdly, the high-altitude subjects have a higher RDW level than those at low altitude, excepting hypoxia, the living habits of residents are different from those in domestic plains, which may also have an impact on RDW levels.

6. Conclusion {#sec6}
=============

Elevated RDW levels may be an independent risk marker for nonvalvular AF, affected by type of AF and altitude. RDW is a simple and economical marker that is routinely taken during complete blood counts and could be assessed in high-altitude residents for AF risk stratification.
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![The nomogram for predicting the occurrence of AF at low altitude (3.5 m). To calculate the risk of AF, first identify the values of each axis, and than draw a vertical line upward to the point axis from each axis. Sum up the points of all variables and locate the value on to the total point line. Subsequently, draw a vertical line down to the risk of AF. AF, atrial fibrillation; RDW: red cell distribution width; MCV: mean corpuscular volume; LAD: left atrial diameter.](CRP2019-6291964.001){#fig1}

![The nomogram for predicting the occurrence of AF at low altitude (2260 m). For example, the RDW (45 points), MCV (75 points), Cr (20 points), and LAD (40 points) arrive at a total of 180 points, which gives an estimated probability of 70% for occurrence of AF. AF, atrial fibrillation; RDW: red cell distribution width, MCV: mean corpuscular volume; Cr, creatinine; LAD: left atrial diameter.](CRP2019-6291964.002){#fig2}

###### 

Baseline characteristics in all subjects at low altitude (3.5 m).

                              AF (*n*=156)     Control (*n*=72)   *χ* ^2^/*T*   *P*
  --------------------------- ---------------- ------------------ ------------- -------
  Male (*n* %)                77.00 (49.40)    31.00 (43.10)      0.785         0.376
  Age (years)                 67.92 ± 10.80    66.26 ± 10.54      0.025         0.280
  Body mass index (kg/m^2^)   25.42 ± 3.93     25.26 ± 2.83       6.75          0.717
  Smoking (*n* %)             22.00 (14.10)    5.00 (6.90)        2.418         0.120
  Diabetes mellitus (*n* %)   31.00 (19.90)    10.00 (13.90)      1.196         0.274
  Hypertension (*n* %)        97.00 (62.20)    48.00 (66.70)      0.428         0.513
  Previous stroke (*n* %)     26.00 (16.70)    11.00 (15.30)      0.070         0.791
  WBC (×10^9^/L)              6.86 ± 1.85      6.68 ± 1.74        1.422         0.484
  RBC (×10^12^/L)             4.45 ± 0.55      4.52 ± 0.44        2.976         0.400
  Hb (g/L)                    139.37 ± 18.59   140.67 ± 15.98     1.008         0.610
  RDW (%CV)                   12.85 ± 0.78     12.59 ± 0.58       2.844         0.013
  HCT (%)                     41.26 ± 5.25     41.22 ± 4.48       2.26          0.954
  MCV (fL)                    92.81 ± 5.57     90.24 ± 9.69       0.019         0.012
  MCHC (g/L)                  337.67 ± 10.87   341.13 ± 8.90      2.972         0.019
  Plt (×10^9^/L)              219.06 ± 58.22   222.13 ± 46.30     1.581         0.695
  MPV (fL)                    9.48 ± 1.00      9.33 ± 0.99        0.116         0.283
  Cr (*μ*mol/L)               70.29 ± 27.62    66.29 ± 17.65      1.606         0.261
  UA (mmol/L)                 325.35 ± 95.49   336.63 ± 87.22     0.670         0.395
  TBIL (*μ*mol/L)             14.64 ± 6.16     12.30 ± 4.18       4.203         0.001
  LAD (mm)                    40.45 ± 7.54     33.78 ± 4.63       14.865        0.001
  LVEDD (mm)                  48.34 ± 6.33     47.13 ± 5.37       1.693         0.163
  IVST (mm)                   9.52 ± 2.32      9.06 ± 1.87        0.461         0.148
  LVPWT (mm)                  9.21 ± 1.90      9.06 ± 3.09        1.503         0.636
  LVEF (%)                    56.70 ± 9.64     60.76 ± 5.54       7.489         0.001
  Aspirin (*n* %)             105.00 (67.30)   57.00 (79.20)      3.368         0.066
  ACEIs or ARBs (*n* %)       49.00 (31.40)    19.00 (26.40)      0.593         0.441
  *β*-blocker (*n* %)         67.00 (42.90)    28.00 (38.90)      0.334         0.563
  CCBs (*n* %)                51.00 (32.70)    22.00 (30.60)      0.103         0.748
  Statins (*n* %)             71.00 (45.50)    38.00 (52.80)      1.042         0.307

AF, atrial fibrillation; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; RDW, red cell distribution width; HCT, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; Plt, platelet count; MPV, mean platelet volume; Cr, creatinine; UA, uric acid; TBIL, total bilirubin; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction.

###### 

Baseline characteristics in all subjects at high altitude (2260 m).

                              AF (*n*=147)      Control (*n*=95)   *χ* ^2^/*T*   *P*
  --------------------------- ----------------- ------------------ ------------- -------
  Male (*n* %)                85.00 (57.80)     46.00 (48.40)      2.055         0.152
  Age (years)                 68.16 ± 9.58      69.28 ± 8.99       1.359         0.363
  Body mass index (kg/m^2)^   25.55 ± 3.43      25.97 ± 2.64       4.467         0.290
  Smoking (*n* %)             25.00 (17.00)     11.00 (11.60)      1.343         0.247
  Diabetes mellitus (*n* %)   30.00 (20.40)     14.00 (14.70)      1.248         0.264
  Hypertension (*n* %)        104.00 (70.70)    64.00 (67.40)      0.311         0.577
  Previous stroke (*n* %)     32.00 (21.80)     15.00 (15.80)      1.318         0.251
  WBC (×10^9^/L)              5.63 ± 1.56       5.72 ± 1.63        0.004         0.668
  RBC (×10^12^/L)             4.91 ± 0.68       4.92 ± 0.57        2.798         0.824
  Hb (g/L)                    152.66 ± 19.07    150.98 ± 17.28     1.245         0.488
  RDW (% CV)                  13.83 ± 1.12      13.10 ± 0.85       5.765         0.001
  HCT (%)                     46.26 ± 5.64      45.82 ± 5.01       1.726         0.538
  MCV (fL)                    94.56 ± 4.93      92.52 ± 9.75       0.110         0.032
  MCHC (g/L)                  330.24 ± 9.84     330.21 ± 9.44      0.038         0.983
  Plt (×10^9^/L)              154.60 ± 52.49    180.98 ± 47.62     0.342         0.001
  MPV (fL)                    12.16 ± 1.52      11.96 ± 1.26       0.041         0.302
  Cr (*μ*mol/L)               80.15 ± 20.68     63.47 ± 14.12      10.889        0.001
  UA (mmol/L)                 374.16 ± 114.71   331.38 ± 83.48     7.007         0.001
  TBIL (*μ*mol/L)             18.00 ± 8.00      16.93 ± 8.09       0.115         0.316
  LAD (mm)                    41.58 ± 6.56      34.21 ± 4.14       15.665        0.001
  LVEDD (mm)                  46.23 ± 4.73      46.01 ± 3.78       4.54          0.689
  IVST (mm)                   10.44 ± 1.49      9.88 ± 1.30        3.288         0.004
  LVPWT (mm)                  10.18 ± 1.30      9.66 ± 1.17        0.306         0.002
  LVEF (%)                    64.70 ± 6.89      64.57 ± 5.70       3.524         0.876
  Aspirin (*n* %)             107.00 (72.80)    59.00 (62.10)      3.058         0.080
  ACEIs or ARBs (*n* %)       40.00 (27.20)     16.00 (16.80)      3.488         0.062
  *β*-blocker (*n* %)         55.00 (37.40)     25.00 (26.30)      3.212         0.073
  CCBs (*n* %)                49.00 (33.30)     30.00 (31.60)      0.081         0.776
  Statins (*n* %)             65.00 (44.20)     39.00 (41.10)      0.236         0.627

AF, atrial fibrillation; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; RDW, red cell distribution width; HCT, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; Plt, platelet count; MPV, mean platelet volume; Cr, creatinine; UA, uric acid; TBIL, total bilirubin; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction.

###### 

Baseline characteristics in patients with AF at two altitudes.

                              Low altitude (3.5 m)   High altitude (2260 m)   *P*                                                                            
  --------------------------- ---------------------- ------------------------ ---------------- -------------------- -------------------- ------------------- -------
  Male (*n* %)                32.00 (41.60)          45.00 (57.00)            31.00 (43.10)    48.00 (62.30)        37.00 (52.90)        46.00 (48.40)       0.075
  Age (years)                 66.92 ± 12.61          68.89 ± 8.66             66.26 ± 10.54    67.23 ± 10.67        69.19 ± 8.17         69.28 ± 8.99        0.250
  BMI (kg/m^2)^               25.10 ± 4.02           25.74 ± 3.84             25.26 ± 2.83     25.18 ± 3.63         25.96 ± 3.18         25.97 ± 2.64        0.351
  Smoking (*n* %)             11.00 (14.30)          11.00 (13.90)            5.00 (6.90)      12.00 (15.60)        13.00 (18.60)        11.00 (11.60)       0.434
  Diabetes mellitus (*n* %)   11.00 (14.30)          20.00 (25.30)            10.00 (13.90)    16.00 (20.80)        14.00 (20.00)        14.00 (14.70)       0.340
  Hypertension (*n* %)        46.00 (59.70)          51.00 (64.60)            48.00 (66.70)    55.00 (71.40)        49.00 (70.00)        64.00 (67.40)       0.704
  Previous stroke (*n* %)     10.00 (13.00)          16.00 (20.30)            11.00 (15.30)    13.00 (16.90)        19.00 (27.10)        15.00 (15.80)       0.276
  WBC (×10^9^/L)              6.89 ± 1.92            6.82 ± 1.79              6.68 ± 1.74      5.56 ± 1.78^a^       5.70 ± 1.28^a^       5.72 ± 1.63^a^      0.001
  RBC (×10^12^/L)             4.40 ± 0.53            4.51 ± 0.58              4.52 ± 0.44      4.90 ± 0.75^a^       4.92 ± 0.59^a^       4.92 ± 0.57^a^      0.001
  Hb (g/L)                    138.48 ± 17.28         140.24 ± 19.85           140.67 ± 15.98   152.55 ± 19.45^a^    152.79 ± 18.78^a^    150.98 ± 17.28^a^   0.001
  RDW (%CV)                   12.71 ± 0.74           12.98 ± 0.80^c^          12.59 ± 0.58     13.52 ± 0.99^a^      14.17 ± 1.16^abc^    13.10 ± 0.85^a^     0.001
  HCT (%)                     40.55 ± 4.75           41.97 ± 5.64             41.22 ± 4.47     46.13 ± 5.68^a^      46.40 ± 5.64^a^      45.82 ± 5.01^a^     0.001
  MCV (fL)                    92.37 ± 5.12           93.24 ± 5.98^c^          90.24 ± 9.69     94.69 ± 5.26^ac^     94.42 ± 4.57         92.52 ± 9.75^a^     0.002
  MCHC (g/L)                  341.39 ± 9.97          334.04 ± 10.52           341.13 ± 8.90    330.94 ± 10.05^a^    329.47 ± 9.62^a^     330.21 ± 9.44^a^    0.001
  Plt (×10^9^/L)              227.84 ± 62.69         210.51 ± 52.50^b^        222.13 ± 46.30   156.94 ± 49.28^ac^   152.03 ± 56.06^ac^   180.98 ± 47.62^a^   0.001
  MPV (fL)                    9.37 ± 0.97            9.58 ± 1.02              9.33 ± 0.99      12.04 ± 1.44^a^      12.29 ± 1.60^a^      11.96 ± 1.26^a^     0.001
  Cr (*μ*mol/L)               69.73 ± 32.44          70.83 ± 22.15            66.29 ± 17.65    81.05 ± 22.14^ac^    79.16 ± 19.05^ac^    63.47 ± 14.12       0.001
  UA (mmol/L)                 310.62 ± 94.97         339.70 ± 94.39           336.63 ± 87.22   362.09 ± 100.77^a^   387.44 ± 127.74^c^   331.38 ± 83.48      0.001
  TBIL (*μ*mol/L)             13.47 ± 6.07           15.79 ± 0.06^c^          12.30 ± 4.18     16.43 ± 5.87^a^      19.73 ± 9.57         16.93 ± 8.09        0.001
  LAD (mm)                    37.00 ± 6.48^c^        43.82 ± 6.99^bc^         33.78 ± 4.63     38.08 ± 4.95^c^      45.43 ± 5.95^bc^     34.21 ± 4.14        0.001
  LVEDD (mm)                  46.83 ± 5.34           49.81 ± 6.88^b^          47.13 ± 5.38     45.97 ± 4.11         46.51 ± 5.34^a^      46.01 ± 3.80        0.001
  IVST (mm)                   9.45 ± 2.25            9.58 ± 2.41              9.06 ± 1.87      10.48 ± 1.60^a^      10.39 ± 1.37         9.88 ± 1.30^a^      0.001
  LVPWT (mm)                  9.26 ± 2.18            9.17 ± 1.60              9.06 ± 3.09      10.21 ± 1.40^a^      10.14 ± 1.20^a^      9.66 ± 1.17         0.001
  LVEF (%)                    59.47 ± 6.63           54.00 ± 11.27            60.76 ± 5.54     65.68 ± 7.10^a^      63.63 ± 6.52^a^      64.57 ± 5.70^a^     0.001
  Aspirin (*n* %)             51.00 (62.20)          54.00 (68.40)            57.00 (79.20)    55.00 (71.40)        52.00 (74.30)        59.00 (62.10)       0.223
  ACEIs or ARBs (*n* %)       22.00 (28.60)          27.00 (34.20)            19.00 (26.40)    19.00 (24.70)        21.00 (30.00)        16.00 (16.80)       0.174
  *β*-blocker (*n* %)         35.00 (45.50)          32.00 (40.50)            28.00 (38.90)    28.00 (36.40)        27.00 (38.60)        25.00 (26.30)       0.180
  CCBs (*n* %)                24.00 (31.20)          27.00 (34.20)            22.00 (30.60)    26.00 (33.80)        23.00 (32.90)        30.00 (31.60)       0.996
  Statins (*n* %)             41.00 (53.20)          30.00 (38.00)            38.00 (52.80)    30.00 (39.00)        35.00 (50.00)        30.00 (31.60)       0.017

AF, atrial fibrillation; PAF, paroxysmal AF; PeAF, persistent AF; BMI, body mass index; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; RDW, red cell distribution width; HCT, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; Plt, platelet count; MPV, mean platelet volume; Cr, creatinine; UA, uric acid; TBIL, total bilirubin; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction; a: compared to the different altitude correspondence groups; b: compared to the same altitude PAF-group; c: compared to the same altitude control group.

###### 

Multiple logistic regression analysis to detect the independent predictors of the occurrence of AF at low altitude (3.5 m).

  Variables   *β*      Wald *χ*^2^   *P*     OR      95% CI
  ----------- -------- ------------- ------- ------- -------------
  RDW         0.523    4.160         0.041   1.687   1.021∼2.789
  MCV         0.074    3.956         0.047   1.077   1.001∼1.159
  TBIL        0.031    0.774         0.379   1.031   0.963∼1.104
  LAD         0.142    21.823        0.001   1.152   1.086∼1.223
  LVEF        −0.032   1.718         0.190   0.968   0.923∼1.016

RDW, red cell distribution width; MCV, mean corpuscular volume; TBIL, total bilirubin; LAD, left atrial diameter; LVEF, left ventricular ejection fraction.

###### 

Multiple logistic regression analysis to detect the independent predictors of the occurrence of AF at high altitude (2260 m).

  Variables   *β*     Wald *χ*^2^   *P*     OR      95% CI
  ----------- ------- ------------- ------- ------- -------------
  RDW         0.562   7.669         0.006   1.755   1.179∼2.613
  MCV         0.084   4.251         0.039   1.088   1.004∼1.178
  Hb          0.003   0.091         0.762   1.003   0.975∼1.019
  Cr          0.063   20.331        0.001   1.065   1.036∼1.094
  UA          0.001   0.070         0.791   1.001   0.996∼1.003
  LAD         0.233   30.785        0.001   1.262   1.162∼1.370
  IVST        0.133   0.163         0.687   1.142   0.599∼2.180
  LVPWT       0.218   0.330         0.565   1.244   0.382∼1.692

RDW, red cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; Cr, creatinine; UA, uric acid; LAD, left atrial diameter; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness.
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